NCT03205761 - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions

Advanced Breast Cancer

Interventions

DRUG

Olaparib

Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.

Trial Locations (16)

10003

Hospital San Pedro de Alcántara, Cáceres

14005

Complejo Hospitalario Universitario Reina Sofía, Córdoba

28007

Hospital General Universitario Gregorio Marañón, Madrid

28033

Centro Oncológico MD Anderson International España, Madrid

28222

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

41009

Hospital Universitario Virgen de la Macarena, Seville

43204

Hospital Universitario San Joan de Reus, Reus

46009

Instituto Valenciano de Oncología (IVO), Valencia

46010

Hospital Clínico Universitario de Valencia, Valencia

50006

"Hospital Clínico Universitario de Zaragoza Lozano Blesa", Zaragoza

50009

Hospital Universitario Miguel Servet, Zaragoza

08916

Hospital Universitario Germans Trias i Pujol, Badalona

08003

Hospital del Mar, Barcelona

08035

Hospital Universitario Vall d´Hebron, Barcelona

08036

Hospital Clinic i Provincial, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona